Genmab has signed an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H Lundbeck (Lundbeck), under which Genmab will create new human antibodies to three targets identified by Lundbeck.
The agreement allows Lundbeck to gain access to Genmab's antibody creation and development capabilities, including its fully automated pre-clinical antibody screening and characterisation capabilities and its proprietary stabilised IgG4 and UniBody therapeutic antibody platforms.
Additionally, Lundbeck is expected to have an option to take selected antibodies into clinical development at its own cost and subject to the payment of milestones and single-digit royalties to Genmab upon successful development and commercialisation.
Genmab is expected to have a similar option to take selected antibodies into clinical development for cancer indications at its own cost and subject to the payment of milestones and single-digit royalties to Lundbeck.
As per the terms of the agreement, Genmab is expected to receive an upfront payment of EUR7.5m and Lundbeck will fully fund the development of the antibodies.
If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately EUR38m, plus single-digit royalties.
Genmab CEO Jan van de Winkel said that the collaboration gives Genmab the opportunity to leverage their antibody technology and expertise and to expand their pipeline into a new and exciting therapeutic area without assuming a financial obligation.
Lundbeck Research head and executive vice president Peter Hongaard Andersen said that the new partnership follows Lundbeck's new R&D strategy to ensure they have efficient platform for the future discovery and development of drugs that would be able to help and treat biologically defined groups of patients with brain diseases.